Multicenter, Randomized, Double-blind, Placebo-controlled Trial With Tadekinig Alfa (r-hIL-18BP) in Patients With IL-18 Driven Monogenic Auto Inflammatory Conditions: NLRC4 Mutation and XIAP Deficiency

Trial Profile

Multicenter, Randomized, Double-blind, Placebo-controlled Trial With Tadekinig Alfa (r-hIL-18BP) in Patients With IL-18 Driven Monogenic Auto Inflammatory Conditions: NLRC4 Mutation and XIAP Deficiency

Recruiting
Phase of Trial: Phase III

Latest Information Update: 22 Jun 2017

At a glance

  • Drugs Tadekinig alfa (Primary)
  • Indications Autoimmune disorders
  • Focus Therapeutic Use
  • Sponsors AB2 Bio
  • Most Recent Events

    • 15 Jun 2017 Status changed from active, no longer recruiting to recruiting.
    • 13 Jun 2017 Status changed from not yet recruiting to active, no longer recruiting.
    • 20 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top